www.mereobiopharma.com Open in urlscan Pro
51.104.28.82  Public Scan

Form analysis
1 forms found in the DOM

GET /search-page/

<form action="/search-page/" class="search-form form-search-common" id="search-overlay-form" method="get">
  <div class="form-group">
    <label for="SearchInput">Search for</label>
    <input type="search" class="form-element" name="q" value="" id="searchinput" aria-describedby="SearchBox" placeholder="Search">
    <button type="submit" class="btn-submit">Go</button>
  </div>
</form>

Text Content

MAIN PANEL HEADING

Some of these cookies are essential to make our site work, while others are
optional, helping us to improve your experience by providing insights into how
the site is being used. If you click on Accept All Cookies, then all cookies,
including optional cookies will be loaded on your browser.

If you close this banner or choose Reject Optional Cookies, then only strictly
necessary cookies remain on your browser. To find out more and to view the
categories of cookies on this site, read our cookie notice(Opens in a new
window)

Accept all cookiesReject optional cookies

--------------------------------------------------------------------------------


NECESSARY COOKIES

Necessary cookies enable core functionality such as page navigation and access
to secure areas. The website cannot function properly without these cookies, and
can only be disabled by changing your browser preferences.

--------------------------------------------------------------------------------


ANALYTICAL COOKIES

Analytical cookies help us to improve our website by collecting and reporting
information on its usage.

Analytical CookiesOnOff

--------------------------------------------------------------------------------

About this tool(Opens in a new window)
 * Working With You
 * Partners
 * HCPs
 * Patient Communities

 * Who We Are
    * Our Vision
    * How We Work
    * History
    * Our Team
    * Careers
    * Governance and Sustainability
    * Case Studies

 * Our Pipeline
    * Overview
    * Setrusumab
    * Alvelestat
    * Etigilimab
    * Navicixizumab
    * Leflutrozole
    * Acumapimod

 * News & Events
    * News
    * Events
    * Case Studies

 * Investors
    * Overview
    * Results, Reports and Presentation
    * NASDAQ
    * Investor Information
    * Corporate Governance

 * Contact Us
    * Overview
    * Offices
    * Medical Enquiries
    * Media Enquiries
    * Get in Touch

Search

Search for Go


UNLOCKING POTENTIAL TO CREATE NEW POSSIBILITIES





OUR MISSION


TO IMPROVE THE LIVES OF PATIENTS WITH RARE DISEASES AND CANCER.

Learn more


OUR PROGRESS

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London
Healthcare Conference

08 November 2022



 

Mereo BioPharma today announced that Dr. Denise Scots-Knight, Chief Executive
Officer of Mereo, will participate in a fireside chat at the Jefferies London
Healthcare Conference on Tuesday, November 15, 2022 at 12:55pm GMT / 07:55am ET.



READ MORE
Investor / Company

MEREO BIOPHARMA REACHES COOPERATION AGREEMENT WITH RUBRIC CAPITAL MANAGEMENT

28 October 2022



Mereo BioPharma Group plc today announced it has entered into a cooperation
agreement (the “Agreement”) with Rubric Capital Management LP (“Rubric”), its
largest shareholder. Pursuant to the Agreement, four new directors – Dr.
Annalisa Jenkins, Dr. Daniel Shames, Mr. Marc Yoskowitz and Mr. Justin Roberts –
will be appointed to the Company’s Board of Directors as soon as practicable.
Concurrent with these appointments taking effect, directors Dr. Peter Fellner,
Dr. Brian Schwartz, Dr. Abdul Mullick and Ms. Anne Hyland will resign from the
Board.



READ MORE
Investor / Company

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

24 October 2022



Mereo BioPharma today announced that it will host a R&D update call on Monday,
October 31, 2022 at 8:00 am ET on the alvelestat (MPH966) program for
alpha-1-antitrypsin deficiency (AATD). The update will include commentary from
and Q&A with leading pulmonary experts, further to the receipt of Fast Track
Designation for alvelestat from the FDA announced on October 17, 2022.



READ MORE
Investor / Pipeline / Alvelestat / Company / HCP

MEREO BIOPHARMA FILES SHAREHOLDER CIRCULAR FOR UPCOMING GENERAL MEETING

21 October 2022



READ MORE
Company / Investor


DRIVEN BY A TRUE UNDERSTANDING OF THE CRITICAL NATURE OF OUR MISSION, WE HARNESS
THE POWER OF SCIENCE AND MEANINGFUL RELATIONSHIPS TO CREATE NEW POSSIBILITIES
FOR PATIENTS WHO NEED THEM.




DISCOVER OUR REVOLUTIONARY THERAPIES

We are committed to helping patients with rare diseases and cancer.

View Our Pipeline


LEARN ABOUT OUR VALUABLE OPPORTUNITIES FOR INVESTORS

We identify and develop therapies with the greatest unrealized, long-term
potential.
Visit Investor Center


SEE HOW WE ARE WORKING WITH YOU

We know the value in collaborating with partners, patient communities and
healthcare professionals.

Find Out More
MREO: US$0.7477
 * Privacy Notice
 * Cookie Notice
 * Urgent Medical Enquiries & Expanded Access
 * Twitter
 * LinkedIn

Mereo Biopharma Group PLC ©2022